Allergy Point-Of-Care Testing Global Market Report 2026

Allergy point-of-care testing refers to rapid diagnostic procedures carried out at or close to the location where patient assessment occurs in order to identify allergic sensitizations. These tests deliver instant outcomes by quantifying specific immunoglobulin E (IgE) antibodies or additional biomarkers associated with allergic responses. They support prompt clinical judgments and the management of allergic disorders without relying on centralized laboratory workflows.

The primary product types of allergy point-of-care testing include rapid specific immunoglobulin E kits, skin prick testing kits, rapid anaphylaxis kits, sample collection devices, and analyzers. Rapid specific immunoglobulin E kits are diagnostic solutions designed to identify allergen-specific antibodies in patient samples, enabling rapid allergy detection. These products are compatible with sample types such as blood, serum or plasma, and fingerstick whole blood, and are applied across allergen categories including food allergens, environmental allergens, and drug and insect venom allergens. Their applications include primary care triage, pediatric clinical assessments, emergency care support, occupational health screening, and pharmacy-led testing, and they are utilized by end users such as specialty clinics, hospitals, retail pharmacies, occupational health providers, and direct-to-consumer channels.

Tariffs are influencing the allergy point-of-care testing market by elevating the cost of imported diagnostic kits, immunoassay reagents, and portable testing devices, thereby reducing affordability and access across healthcare environments. This impact is especially notable in segments such as rapid specific IgE test kits and portable point-of-care analyzers, with regions including North America and Asia-Pacific being most affected due to their dependence on imported diagnostic components. Hospitals, specialty clinics, and retail pharmacy-based testing services are experiencing increased procurement expenses and disruptions in supply continuity. However, tariffs are simultaneously fostering domestic production of diagnostic kits and reinforcing regional supply chains, which supports long-term market stability and innovation in rapid allergy testing solutions.

The allergy point-of-care testing market research report is one of a series of new reports from The Business Research Company that provides allergy point-of-care testing market statistics, including allergy point-of-care testing industry global market size, regional shares, competitors with a allergy point-of-care testing market share, detailed allergy point-of-care testing market segments, market trends and opportunities, and any further data you may need to thrive in the allergy point-of-care testing industry. This allergy point-of-care testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The allergy point-of-care testing market size has grown rapidly in recent years. It will grow from $1.33 billion in 2025 to $1.49 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to rising prevalence of allergic disorders globally, increasing clinical awareness of early allergy diagnosis, expansion of immunoassay technologies in diagnostics, growth in hospital based laboratory testing infrastructure, increasing pediatric allergy cases.

The allergy point-of-care testing market size is expected to see rapid growth in the next few years. It will grow to $2.34 billion by 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to expansion of point of care diagnostic adoption, growth in personalized medicine approaches for allergy management, increasing demand for rapid home based testing solutions, integration of ai enabled diagnostic interpretation tools, rising healthcare decentralization and outpatient care expansion. Major trends in the forecast period include increasing adoption of rapid immunoglobulin e based allergy diagnostics, rising demand for portable point of care testing devices, expansion of decentralized allergy screening in primary care settings, growth in immunoassay based rapid allergy detection kits, increasing integration of digital health platforms in allergy testing workflows.

The growing prevalence of allergic conditions is anticipated to drive the expansion of the allergy point of care testing market forward. Allergic conditions are immune system disorders in which the body reacts excessively to harmless substances, resulting in symptoms such as sneezing, skin rashes, and breathing difficulties. The prevalence of allergic conditions is increasing due to greater exposure to environmental allergens, including pollen, dust, and pollution, which provoke immune system overreactions in susceptible individuals. Allergy point-of-care testing allows fast and convenient identification of specific allergens, enabling healthcare providers to quickly determine triggers, support tailored treatment strategies, and assist individuals in effectively managing and reducing the impact of allergic conditions. For instance, in November 2025, according to Asthma Australia, an Australia-based non-profit organization, 322 women died from asthma last year compared with 156 men, which is more than twice as many. This pattern has remained unchanged since 2023, with half of the 478 total deaths occurring in women aged 75 and over. Therefore, the growing prevalence of allergic conditions is contributing to the growth of the allergy point of care testing market.

Leading companies operating in the allergy point-of-care testing market are focusing on developing innovative products such as semi-quantitative point-of-care diagnostic devices to deliver rapid, accurate allergy test results in clinical settings. Semi-quantitative point-of-care diagnostic devices are tools that measure approximate levels of specific biomarkers, such as IgE, directly at the clinic, providing rapid, reliable results that enable healthcare providers to quickly assess the severity of allergic responses and make immediate, informed treatment decisions without waiting for traditional laboratory tests. For example, in June 2024, Kenota Health, a Canada-based medical technology company, received U. S. Food and Drug Administration (FDA) clearance and a CLIA waiver for the Kenota 1 Total IgE test system, enabling its use in point-of-care clinical settings. The Kenota 1 system is a semi-quantitative diagnostic device that measures total IgE levels from a minimal fingerstick blood sample, delivering results in under 30 minutes with automated operation, unlike traditional laboratory IgE tests that require venous blood draws and several days for results. The system is designed for rapid, in-office allergy assessment, offering features such as a small blood volume requirement of 4.5 microliters per test, easy-to-use operation, and the capacity to run 15-60 tests per session. Its applications include supporting the diagnosis of IgE-mediated allergic disorders and enabling clinicians to make immediate patient care decisions, streamlining allergy management and improving patient outcomes.

The increasing healthcare expenditure is anticipated to drive the expansion of the allergy point-of-care testing market forward. Healthcare expenditure refers to the total financial resources spent on health services, medical products, public health programs, and healthcare infrastructure by governments, private entities, and individuals. Healthcare expenditure is rising due to the growing demand for medical services, as more patients require consultations, treatments, and diagnostic procedures, which increases overall healthcare spending. Healthcare expenditure supports the growth of allergy point-of-care (POC) testing by enabling investment in advanced diagnostic technologies, promoting rapid testing at or near patient care settings, reducing dependence on centralized laboratories, and enhancing efficiency along with overall healthcare outcomes. For instance, in January 2026, according to the Centers for Medicare & Medicaid Services, a US-based government agency, in 2024, National Health Expenditure (NHE) rose by 7.2% to reach $5.3 trillion, averaging $15,474 per person, and accounted for 18.0% of the Gross Domestic Product (GDP). Therefore, the increasing healthcare expenditure is driving the growth of the allergy point-of-care testing market.

Major companies operating in the allergy point-of-care testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Hitachi Chemical Diagnostic Inc. , Thermo Fisher Scientific Inc. , Abbott Laboratories, Eurofins Scientific SE, bioMerieux SA, Quidel Corporation, EUROIMMUN Medizinische Labordiagnostika AG, R-Biopharm AG, HOB Biotech Group Corp. Ltd. , Hycor Biomedical Inc. , Omega Diagnostics Ltd, Lincoln Diagnostics Inc. , Alerchek Inc. , Abionic SA, Kenota Health Inc.

North America was the dominating region in the allergy point-of-care testing market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the allergy point-of-care testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the allergy point-of-care testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allergy point-of-care testing market consists of revenues earned by entities by providing services such as allergy screening, rapid diagnostic testing, patient sample collection, immunoassay analysis, result interpretation, counseling and consultation, allergy monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The allergy point-of-care testing market also includes sales of point-of-care test kits, lancets, test strips, immunoassay devices, blood collection devices, skin prick test devices, lateral flow assay cassettes, analyzers, sample collection tubes, and diagnostic reagents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Allergy Point-Of-Care Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses allergy point-of-care testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for allergy point-of-care testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The allergy point-of-care testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Rapid Specific Immunoglobulin E Kits; Skin Prick Testing Kits; Rapid Anaphylaxis Kits; Sample Collection Devices; Analyzers
• 2) By Sample Type: Blood; Serum Or Plasma; Fingerstick Whole Blood
• 3) By Allergen Type: Food Allergens; Environmental Allergens; Drug And Insect Venom Allergens
• 4) By Application Focus: Primary Care Triage; Pediatric Clinic Workups; Emergency Care Support; Occupational Health Screening; Pharmacy Led Testing
• 5) By End User: Specialty Clinics; Hospitals; Retail Pharmacies; Occupational Health Providers; Direct To Consumer
• Subsegments:
• 1) By Rapid Specific Immunoglobulin E Kits: Food Allergy Kits; Inhalant Allergy Kits; Drug Allergy Kits; Environmental Allergy Kits
• 2) By Skin Prick Testing Kits: Standard Allergen Panels; Custom Allergen Panels; Pediatric Testing Kits; Adult Testing Kits
• 3) By Rapid Anaphylaxis Kits: Epinephrine Auto Injectors; Immediate Reaction Detection Kits; Allergic Response Monitoring Kits; Emergency Response Kits
• 4) By Sample Collection Devices: Blood Collection Devices; Saliva Collection Devices; Skin Prick Sampling Devices; Capillary Sampling Devices
• 5) By Analyzers: Immunoassay Analyzers; Chemiluminescence Analyzers; Integrated Analyzer Systems; Portable Point Of Care Analyzers
• Companies Mentioned: Siemens Healthineers AG; F. Hoffmann-La Roche Ltd; Hitachi Chemical Diagnostic Inc.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Eurofins Scientific SE; bioMerieux SA; Quidel Corporation; EUROIMMUN Medizinische Labordiagnostika AG; R-Biopharm AG; HOB Biotech Group Corp. Ltd.; Hycor Biomedical Inc.; Omega Diagnostics Ltd; Lincoln Diagnostics Inc.; Alerchek Inc.; Abionic SA; Kenota Health Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.